Provided by Tiger Trade Technology Pte. Ltd.

OPTHEA LTD

0.600
0.000
Volume:- -
Turnover:- -
Market Cap:820.79M
PE:-2.96
High:0.600
Open:0.600
Low:0.600
Close:0.600
52wk High:1.050
52wk Low:0.590
Shares:1.37B
Float Shares:786.04M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.203
EPS(LYR):-0.133
ROE:-3383.08%
ROA:-79.28%
PB:-2.89
PE(LYR):-4.51

Loading ...

Company Profile

Company Name:
OPTHEA LTD
Exchange:
ASX
Establishment Date:
1984
Employees:
33
Office Location:
Level 9,505 Little Collins Street,Melbourne,Victoria,Australia
Zip Code:
3000
Fax:
61 3 9824 0083
Introduction:
Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase Ib/IIa clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.